Most Tourette patients report benefit from medical cannabis in real-world use

The overall global impression of efficacy score was 3.85 out of 5. Thirty-eight of 42 patients reported some benefit, most commonly tic reduction, better sleep, and improved mood. Ten patients with more than one year of use chose to stop treatment for various reasons, including one case of psychosis.

Cross-sectional phone interview survey of 42 Tourette syndrome patients (33 males, mean age 34.5) treated with medical cannabis at a single center. Efficacy rated on a 1-5 Likert scale.

Controlled trials of cannabis for Tourette syndrome are few and small. Real-world data from a clinical setting helps fill the evidence gap, even if it cannot establish efficacy the way a trial can.

Tourette syndrome has limited effective treatments, and many patients are dissatisfied with existing options. Cannabis represents an alternative that many patients find helpful, but the one psychosis case underscores the need for monitoring.

Single-center survey with no control group or blinding. Subjective self-report measures only. Selection bias likely (patients who found benefit may be more willing to participate). No standardized tic severity measurements.